220 related articles for article (PubMed ID: 36508306)
1. Regulatory T cells and systemic vasculitis.
Mirouse A; Cacoub P; Saadoun D
Curr Opin Rheumatol; 2023 Jan; 35(1):25-30. PubMed ID: 36508306
[TBL] [Abstract][Full Text] [Related]
2. Trends in health care of patients with vasculitides, including giant cell arteritis, Takayasu arteritis, ANCA-associated vasculitis and Behçet's disease: cross-sectional data of the German National Database 2007-2021.
Henes J; Richter JG; Thiele K; Kiltz U; Callhoff J; Albrecht K
Rheumatol Int; 2024 Mar; 44(3):497-507. PubMed ID: 38180499
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular risk in vasculitis.
Misra DP; Sharma A; Karpouzas GA; Kitas GD
Best Pract Res Clin Rheumatol; 2023 Mar; 37(1):101831. PubMed ID: 37302927
[TBL] [Abstract][Full Text] [Related]
4. Biologic treatment of large-vessel vasculitides.
Schäfer VS; Zwerina J
Curr Opin Rheumatol; 2012 Jan; 24(1):31-7. PubMed ID: 22089099
[TBL] [Abstract][Full Text] [Related]
5. Biotherapies in large vessel vasculitis.
Ferfar Y; Mirault T; Desbois AC; Comarmond C; Messas E; Savey L; Domont F; Cacoub P; Saadoun D
Autoimmun Rev; 2016 Jun; 15(6):544-51. PubMed ID: 26883459
[TBL] [Abstract][Full Text] [Related]
6. B-cell-targeted therapy in systemic vasculitis.
Lally L; Spiera R
Curr Opin Rheumatol; 2016 Jan; 28(1):15-20. PubMed ID: 26599379
[TBL] [Abstract][Full Text] [Related]
7. Clonal haematopoiesis across the age spectrum of vasculitis patients with Takayasu's arteritis, ANCA-associated vasculitis and giant cell arteritis.
Gutierrez-Rodrigues F; Wells KV; Jones AI; Hironaka D; Rankin C; Gadina M; Sikora KA; Alemu L; Calado RT; Quinn KA; Patel B; Young NS; Grayson PC
Ann Rheum Dis; 2024 Mar; 83(4):508-517. PubMed ID: 38049983
[TBL] [Abstract][Full Text] [Related]
8. Th1 and Th17 cytokines drive inflammation in Takayasu arteritis.
Saadoun D; Garrido M; Comarmond C; Desbois AC; Domont F; Savey L; Terrier B; Geri G; Rosenzwajg M; Klatzmann D; Fourret P; Cluzel P; Chiche L; Gaudric J; Koskas F; Cacoub P
Arthritis Rheumatol; 2015 May; 67(5):1353-60. PubMed ID: 25604824
[TBL] [Abstract][Full Text] [Related]
9. Novel aspects of regulatory T cell dysfunction as a therapeutic target in giant cell arteritis.
Adriawan IR; Atschekzei F; Dittrich-Breiholz O; Garantziotis P; Hirsch S; Risser LM; Kosanke M; Schmidt RE; Witte T; Sogkas G
Ann Rheum Dis; 2022 Jan; 81(1):124-131. PubMed ID: 34583923
[TBL] [Abstract][Full Text] [Related]
10. Epidemiology of systemic vasculitis.
Ozguler Y; Esatoglu SN; Hatemi G
Curr Opin Rheumatol; 2024 Jan; 36(1):21-26. PubMed ID: 37800639
[TBL] [Abstract][Full Text] [Related]
11. Clinical relevance of elevated serum thrombomodulin and soluble E-selectin in patients with Wegener's granulomatosis and other systemic vasculitides.
Boehme MW; Schmitt WH; Youinou P; Stremmel WR; Gross WL
Am J Med; 1996 Oct; 101(4):387-94. PubMed ID: 8873509
[TBL] [Abstract][Full Text] [Related]
12. Systemic vasculitides: a critical digest of the most recent literature.
Stagnaro C; Cioffi E; Talarico R; Della Rossa A
Clin Exp Rheumatol; 2015; 33(2 Suppl 89):S-145-54. PubMed ID: 26016767
[TBL] [Abstract][Full Text] [Related]
13. Vasculitis research: Current trends and future perspectives.
Misra DP; Naidu GSRSNK; Agarwal V; Sharma A
Int J Rheum Dis; 2019 Jan; 22 Suppl 1():10-20. PubMed ID: 30168260
[TBL] [Abstract][Full Text] [Related]
14. Neutrophil activation in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis and large-vessel vasculitis.
Michailidou D; Duvvuri B; Kuley R; Cuthbertson D; Grayson PC; Khalidi NA; Koening CL; Langford CA; McAlear CA; Moreland LW; Pagnoux C; Seo P; Specks U; Sreih AG; Warrington KJ; Mustelin T; Monach PA; Merkel PA; Lood C
Arthritis Res Ther; 2022 Jun; 24(1):160. PubMed ID: 35768848
[TBL] [Abstract][Full Text] [Related]
15. PTX3 Intercepts Vascular Inflammation in Systemic Immune-Mediated Diseases.
Ramirez GA; Rovere-Querini P; Blasi M; Sartorelli S; Di Chio MC; Baldini M; De Lorenzo R; Bozzolo EP; Leone R; Mantovani A; Manfredi AA; Tombetti E
Front Immunol; 2019; 10():1135. PubMed ID: 31191526
[TBL] [Abstract][Full Text] [Related]
16. Patient Reported Outcomes in Large Vessel Vasculitides.
Robson J; Mackie S; Hill C
Curr Rheumatol Rep; 2021 Jan; 23(2):7. PubMed ID: 33511455
[TBL] [Abstract][Full Text] [Related]
17. Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature.
Kötter I; Henes JC; Wagner AD; Loock J; Gross WL
Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S114-29. PubMed ID: 22640655
[TBL] [Abstract][Full Text] [Related]
18. One year in review 2018: systemic vasculitis.
Elefante E; Bond M; Monti S; Lepri G; Cavallaro E; Felicetti M; Calabresi E; Posarelli C; Talarico R; Quartuccio L; Baldini C
Clin Exp Rheumatol; 2018; 36 Suppl 111(2):12-32. PubMed ID: 29799395
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary manifestations of large, medium, and variable vessel vasculitis.
Adams TN; Zhang D; Batra K; Fitzgerald JE
Respir Med; 2018 Dec; 145():182-191. PubMed ID: 30509707
[TBL] [Abstract][Full Text] [Related]
20. [Large Vessel Vasculitides: Giant Cell Arteritis and Takayasu Arteritis - Similarities and Differences].
Gloor AD; Christ L
Ther Umsch; 2022 Jun; 79(5):221-228. PubMed ID: 35583023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
